Ian Stolerman received the BPharm degree of the School of Pharmacy, University of London, in 1964 and a Ph.D. in Psychopharmacology at University College London in 1969. This was followed by postdoctoral experience at the Albert Einstein College of Medicine (New York) and the University of California, Los Angeles. He then moved to Birmingham to become a member of the Medical Research Council Neuropharmacology Unit. In 1980 he relocated to the Institute of Psychiatry, London as a member of the MRC External Scientific Staff. He headed the Institute’s Section of Behavioural Pharmacology and was co-chair of the its addictions Interdisciplinary Research Group. His research included studies on  nicotine and on mixtures of psychoactive drugs and was funded primarily by the UK Medical Research Council, the US National Institute on Drug Abuse and the Wellcome Trust. Ian Stolerman was a founder of the European Behavioural Pharmacology Society and became its first President in 1986. Hereceived the title Professor of Behavioural Pharmacology in 1995. From 1992 to 2005 he served as Co-Editor of the journal Drug and Alcohol Dependence. He was also on the Councils of the British Association for Psychopharmacology and the Research Defence Society, was President of the International Society of Addiction Journal Editors and of the Society for Stimulus Properties of Drugs. Ian Stolerman established the Drug Discrimination Database, a unique research tool for both students and research professionals interested in the neurobiological bases of addiction, that was funded for nearly 30 years by the US National Institute on Drug Abuse. In 2008 the Institute of Psychiatry, King’s College London, honored him with the title of Emeritus Professor of Behavioural Pharmacology. He was the Editor-in-Chief of the first edition of the Encyclopedia of Psychopharmacology (2010). Lawrence Price attended the University of Michigan, where he received a B.S. with highest honors in psychology and high distinction in 1974, followed by an M.D. in 1978. After an internship in internal medicine at Norwalk Hospital in Norwalk, Connecticut, he completed residency and fellowship training in psychiatry at Yale University. From 1982 until 1996, he was on the faculty in the Department of Psychiatry at Yale University, serving as Associate Professor and Director of the Clinical Neuroscience Research Unit at the Connecticut Mental Health Center in New Haven, Connecticut. Since 1996, he has been Professor of Psychiatry and Human Behavior at Brown University. From 1996 until 2012, he was Clinical Director, Director of Research, and Chair of the Institutional Review Board at Butler Hospital in Providence, Rhode Island, subsequently serving as Chief Medical Officer from 2012 until 2014. He is currently President of Butler Hospital and Executive Chief of the Brain and Behavioral Health Service Line of Care New England. Dr. Price’s primary research interests have involved the phenomenology, clinical psychopharmacology, neuropharmacology, and neurobiology of mood, anxiety, and addictive disorders. He has published nearly 450 scientific papers, and was identified by the Institute for Scientific Information as one of the top ten authors of high-impact papers in psychiatry from 1990 to 1999. A Distinguished Fellow of the American Psychiatric Association and a Fellow of the American College of Neuropsychopharmacology, he is one of the principal developers of the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), the standard assessment tool for OCD. In addition to his research activities, Dr. Price has received numerous awards for his teaching, mentoring, and clinical work, and is Editor of The Brown University Psychopharmacology Update and a Principal Editor for clinical psychopharmacology of Psychopharmacology.

"This is, as before, a well-presented, well thought-out, up-to-date reference book on an important subject, which can be thoroughly recommended to its potential readers. ... All academic libraries catering for postgraduate study or research in the neurosciences in general, and psychopharmacology in particular, can be warmly recommended to consider this book ... ." (Martin Guha, Reference Reviews, Vol. 29 (8), 2015) "This is a very comprehensive atlas and text (one-volume) concerning psychoneuropharmacology in human trials and animal studies. ... This is a perfect textbook for psychiatrists, psychopharmacologists, researchers, neuropharmacologists, fellows, residents, neurologists, and medical students involved in psychopharmacology work in the laboratory and the clinic." (Joseph J. Grenier, Amazon.com, April, 2015)

• From the Contents: ABC Transporters.- Absorption.- Abstinence.- Abuse.- Abuse Liability.- Acamprosate.- BAC.- Balanced Placebo Design.- Barbital.- Barbiturates.- Basal Forebrain Cholinergic Neurons.- Behavioral Allocation Function.- Cabergoline.- Cachexia.- Caffeine.- Caffeine Withdrawal Syndrome.- Caffeinism.- cAMP.- DARPP-32.- db/db Mouse.- D-cycloserine.- Decision Making.- Declarative and Non-Declarative Memory.- Declarative Memory.- Early Ventral Hippocampal Lesion Model.- Eating and Appetite.- Eating Disorder: Anorexia Nervosa.- Eating Disorders: Animal Models.- Eating Disorders: Binge-Eating.- Echolalia.- FAA.- Face Validity.- Facial Dysmorphology.- False Memory.- False Negative.- False Positive.- G protein-Coupled Receptors.- GABA.- GABAA Receptor.- GABAergic Transmission.- Gabapentin.- Galantamine.- Habit Reversal Therapy.- Habit Reversal Training.- Habituation.- Half-Life.- Hallucinations.- Hallucinogen Abuse.- IACUC.- ICD.- Idiopathic.- Imaging Mass Spectrometry.- Imipramine.- Impairment of Functioning; Measurement Scales.- Kappa-Opioid Agonists.- Kappa-Receptor.- Keratotic Lesion.- Ketamine.- Ketamine.- Khat.- L-Alpha-Acetyl-Methadol.- Lamotrigine.- Lanreotide.- Latent Inhibition.- Latin Square Design.- Laxatives.- Magnetic Resonance Imaging.- Major and Minor and Mixed Anxiety-Depressive Disorders.- Major Tranquilizer.- Mania.- MAO-B Inhibitor.- Mass Spectrometry.- N-Acetylcysteine.- Nafion.- Naloxone.- Naltrexone.- N-Arachidonylethanolamine.- Narcolepsy.- ob/ob Mouse.- Obsessions.- Obsessive-Compulsive Anxiety Disorders.- Occasion Setting with Drugs.- Octreotide.- Off-Label Use of Drugs.- P300.- Pain.- Pain and Psychopharmacology.- Pair-Feeding.- Palatability.- Paliperidone.- qEEG.- QT Interval.- Quality of Life.- Quazepam.- Quetiapine.- Radial Arm Maze.- Radionuclide.- Radiopharmaceutical.- Radiotracer.- Randomized Controlled Trials.- Rapamycin.- Saporin.- Satiety.- Saturation Binding Curve.- Scalar Property.- Schedule I.- Schedule II.- Tachykinins.-Tachyphylaxis.- Tandospirone.- Tardive Dyskinesia.- Taste Reactivity Test.- Temazepam.- Ubiquitin-Proteasome System.- Ultrasonic.- Ultrasonic Vocalizations.- Ultrasonic Vocalizations.- Unblocking.- Unconditional Response.- Vaccination.- Vaccines and Drug-Specific Antibodies.- Vagus Nerve Stimulation.- Valproic Acid.- Values-Based Medicine.- Varenicline.- Wakefulness.- Water Maze.- Whole-Cell Recording.- Wisconsin Card Sorting Test.- Wisconsin General Test Apparatus.- Withdrawal Syndromes.- Yale-Brown Obsessive-Compulsive Scale.- Yohimbine.- Zaleplon.- Zero-Order Elimination Kinetics.- Ziprasidone.- Zolpidem.- Zonisamide.- Zopiclone.

Ian Stolerman received the BPharm degree of the School of Pharmacy, University of London, in 1964 and a Ph.D. in Psychopharmacology at University College London in 1969. This was followed by postdoctoral experience at the Albert Einstein College of Medicine (New York) and the University of California, Los Angeles. He then moved to Birmingham to become a member of the Medical Research Council Neuropharmacology Unit. In 1980 he relocated to the Institute of Psychiatry, London as a member of the MRC External Scientific Staff. He headed the Institute’s Section of Behavioural Pharmacology and was co-chair of the its addictions Interdisciplinary Research Group. His research included studies on  nicotine and on mixtures of psychoactive drugs and was funded primarily by the UK Medical Research Council, the US National Institute on Drug Abuse and the Wellcome Trust. Ian Stolerman was a founder of the European Behavioural Pharmacology Society and became its first President in 1986. Hereceived the title Professor of Behavioural Pharmacology in 1995. From 1992 to 2005 he served as Co-Editor of the journal Drug and Alcohol Dependence. He was also on the Councils of the British Association for Psychopharmacology and the Research Defence Society, was President of the International Society of Addiction Journal Editors and of the Society for Stimulus Properties of Drugs. Ian Stolerman established the Drug Discrimination Database, a unique research tool for both students and research professionals interested in the neurobiological bases of addiction, that was funded for nearly 30 years by the US National Institute on Drug Abuse. In 2008 the Institute of Psychiatry, King’s College London, honored him with the title of Emeritus Professor of Behavioural Pharmacology. He was the Editor-in-Chief of the first edition of the Encyclopedia of Psychopharmacology (2010). Lawrence Price attended the University of Michigan, where he received a B.S. with highest honors in psychology and high distinction in 1974, followed by an M.D. in 1978. After an internship in internal medicine at Norwalk Hospital in Norwalk, Connecticut, he completed residency and fellowship training in psychiatry at Yale University. From 1982 until 1996, he was on the faculty in the Department of Psychiatry at Yale University, serving as Associate Professor and Director of the Clinical Neuroscience Research Unit at the Connecticut Mental Health Center in New Haven, Connecticut. Since 1996, he has been Professor of Psychiatry and Human Behavior at Brown University. From 1996 until 2012, he was Clinical Director, Director of Research, and Chair of the Institutional Review Board at Butler Hospital in Providence, Rhode Island, subsequently serving as Chief Medical Officer from 2012 until 2014. He is currently President of Butler Hospital and Executive Chief of the Brain and Behavioral Health Service Line of Care New England. Dr. Price’s primary research interests have involved the phenomenology, clinical psychopharmacology, neuropharmacology, and neurobiology of mood, anxiety, and addictive disorders. He has published nearly 450 scientific papers, and was identified by the Institute for Scientific Information as one of the top ten authors of high-impact papers in psychiatry from 1990 to 1999. A Distinguished Fellow of the American Psychiatric Association and a Fellow of the American College of Neuropsychopharmacology, he is one of the principal developers of the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), the standard assessment tool for OCD. In addition to his research activities, Dr. Price has received numerous awards for his teaching, mentoring, and clinical work, and is Editor of The Brown University Psychopharmacology Update and a Principal Editor for clinical psychopharmacology of Psychopharmacology.

"This is, as before, a well-presented, well thought-out, up-to-date reference book on an important subject, which can be thoroughly recommended to its potential readers. ... All academic libraries catering for postgraduate study or research in the neurosciences in general, and psychopharmacology in particular, can be warmly recommended to consider this book ... ." (Martin Guha, Reference Reviews, Vol. 29 (8), 2015) "This is a very comprehensive atlas and text (one-volume) concerning psychoneuropharmacology in human trials and animal studies. ... This is a perfect textbook for psychiatrists, psychopharmacologists, researchers, neuropharmacologists, fellows, residents, neurologists, and medical students involved in psychopharmacology work in the laboratory and the clinic." (Joseph J. Grenier, Amazon.com, April, 2015)

• From the Contents: ABC Transporters.- Absorption.- Abstinence.- Abuse.- Abuse Liability.- Acamprosate.- BAC.- Balanced Placebo Design.- Barbital.- Barbiturates.- Basal Forebrain Cholinergic Neurons.- Behavioral Allocation Function.- Cabergoline.- Cachexia.- Caffeine.- Caffeine Withdrawal Syndrome.- Caffeinism.- cAMP.- DARPP-32.- db/db Mouse.- D-cycloserine.- Decision Making.- Declarative and Non-Declarative Memory.- Declarative Memory.- Early Ventral Hippocampal Lesion Model.- Eating and Appetite.- Eating Disorder: Anorexia Nervosa.- Eating Disorders: Animal Models.- Eating Disorders: Binge-Eating.- Echolalia.- FAA.- Face Validity.- Facial Dysmorphology.- False Memory.- False Negative.- False Positive.- G protein-Coupled Receptors.- GABA.- GABAA Receptor.- GABAergic Transmission.- Gabapentin.- Galantamine.- Habit Reversal Therapy.- Habit Reversal Training.- Habituation.- Half-Life.- Hallucinations.- Hallucinogen Abuse.- IACUC.- ICD.- Idiopathic.- Imaging Mass Spectrometry.- Imipramine.- Impairment of Functioning; Measurement Scales.- Kappa-Opioid Agonists.- Kappa-Receptor.- Keratotic Lesion.- Ketamine.- Ketamine.- Khat.- L-Alpha-Acetyl-Methadol.- Lamotrigine.- Lanreotide.- Latent Inhibition.- Latin Square Design.- Laxatives.- Magnetic Resonance Imaging.- Major and Minor and Mixed Anxiety-Depressive Disorders.- Major Tranquilizer.- Mania.- MAO-B Inhibitor.- Mass Spectrometry.- N-Acetylcysteine.- Nafion.- Naloxone.- Naltrexone.- N-Arachidonylethanolamine.- Narcolepsy.- ob/ob Mouse.- Obsessions.- Obsessive-Compulsive Anxiety Disorders.- Occasion Setting with Drugs.- Octreotide.- Off-Label Use of Drugs.- P300.- Pain.- Pain and Psychopharmacology.- Pair-Feeding.- Palatability.- Paliperidone.- qEEG.- QT Interval.- Quality of Life.- Quazepam.- Quetiapine.- Radial Arm Maze.- Radionuclide.- Radiopharmaceutical.- Radiotracer.- Randomized Controlled Trials.- Rapamycin.- Saporin.- Satiety.- Saturation Binding Curve.- Scalar Property.- Schedule I.- Schedule II.- Tachykinins.-Tachyphylaxis.- Tandospirone.- Tardive Dyskinesia.- Taste Reactivity Test.- Temazepam.- Ubiquitin-Proteasome System.- Ultrasonic.- Ultrasonic Vocalizations.- Ultrasonic Vocalizations.- Unblocking.- Unconditional Response.- Vaccination.- Vaccines and Drug-Specific Antibodies.- Vagus Nerve Stimulation.- Valproic Acid.- Values-Based Medicine.- Varenicline.- Wakefulness.- Water Maze.- Whole-Cell Recording.- Wisconsin Card Sorting Test.- Wisconsin General Test Apparatus.- Withdrawal Syndromes.- Yale-Brown Obsessive-Compulsive Scale.- Yohimbine.- Zaleplon.- Zero-Order Elimination Kinetics.- Ziprasidone.- Zolpidem.- Zonisamide.- Zopiclone.

Ian Stolerman received the BPharm degree of the School of Pharmacy, University of London, in 1964 and a Ph.D. in Psychopharmacology at University College London in 1969. This was followed by postdoctoral experience at the Albert Einstein College of Medicine (New York) and the University of California, Los Angeles. He then moved to Birmingham to become a member of the Medical Research Council Neuropharmacology Unit. In 1980 he relocated to the Institute of Psychiatry, London as a member of the MRC External Scientific Staff. He headed the Institute’s Section of Behavioural Pharmacology and was co-chair of the its addictions Interdisciplinary Research Group. His research included studies on  nicotine and on mixtures of psychoactive drugs and was funded primarily by the UK Medical Research Council, the US National Institute on Drug Abuse and the Wellcome Trust. Ian Stolerman was a founder of the European Behavioural Pharmacology Society and became its first President in 1986. Hereceived the title Professor of Behavioural Pharmacology in 1995. From 1992 to 2005 he served as Co-Editor of the journal Drug and Alcohol Dependence. He was also on the Councils of the British Association for Psychopharmacology and the Research Defence Society, was President of the International Society of Addiction Journal Editors and of the Society for Stimulus Properties of Drugs. Ian Stolerman established the Drug Discrimination Database, a unique research tool for both students and research professionals interested in the neurobiological bases of addiction, that was funded for nearly 30 years by the US National Institute on Drug Abuse. In 2008 the Institute of Psychiatry, King’s College London, honored him with the title of Emeritus Professor of Behavioural Pharmacology. He was the Editor-in-Chief of the first edition of the Encyclopedia of Psychopharmacology (2010). Lawrence Price attended the University of Michigan, where he received a B.S. with highest honors in psychology and high distinction in 1974, followed by an M.D. in 1978. After an internship in internal medicine at Norwalk Hospital in Norwalk, Connecticut, he completed residency and fellowship training in psychiatry at Yale University. From 1982 until 1996, he was on the faculty in the Department of Psychiatry at Yale University, serving as Associate Professor and Director of the Clinical Neuroscience Research Unit at the Connecticut Mental Health Center in New Haven, Connecticut. Since 1996, he has been Professor of Psychiatry and Human Behavior at Brown University. From 1996 until 2012, he was Clinical Director, Director of Research, and Chair of the Institutional Review Board at Butler Hospital in Providence, Rhode Island, subsequently serving as Chief Medical Officer from 2012 until 2014. He is currently President of Butler Hospital and Executive Chief of the Brain and Behavioral Health Service Line of Care New England. Dr. Price’s primary research interests have involved the phenomenology, clinical psychopharmacology, neuropharmacology, and neurobiology of mood, anxiety, and addictive disorders. He has published nearly 450 scientific papers, and was identified by the Institute for Scientific Information as one of the top ten authors of high-impact papers in psychiatry from 1990 to 1999. A Distinguished Fellow of the American Psychiatric Association and a Fellow of the American College of Neuropsychopharmacology, he is one of the principal developers of the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), the standard assessment tool for OCD. In addition to his research activities, Dr. Price has received numerous awards for his teaching, mentoring, and clinical work, and is Editor of The Brown University Psychopharmacology Update and a Principal Editor for clinical psychopharmacology of Psychopharmacology.

"This is, as before, a well-presented, well thought-out, up-to-date reference book on an important subject, which can be thoroughly recommended to its potential readers. ... All academic libraries catering for postgraduate study or research in the neurosciences in general, and psychopharmacology in particular, can be warmly recommended to consider this book ... ." (Martin Guha, Reference Reviews, Vol. 29 (8), 2015) "This is a very comprehensive atlas and text (one-volume) concerning psychoneuropharmacology in human trials and animal studies. ... This is a perfect textbook for psychiatrists, psychopharmacologists, researchers, neuropharmacologists, fellows, residents, neurologists, and medical students involved in psychopharmacology work in the laboratory and the clinic." (Joseph J. Grenier, Amazon.com, April, 2015)

• From the Contents: ABC Transporters.- Absorption.- Abstinence.- Abuse.- Abuse Liability.- Acamprosate.- BAC.- Balanced Placebo Design.- Barbital.- Barbiturates.- Basal Forebrain Cholinergic Neurons.- Behavioral Allocation Function.- Cabergoline.- Cachexia.- Caffeine.- Caffeine Withdrawal Syndrome.- Caffeinism.- cAMP.- DARPP-32.- db/db Mouse.- D-cycloserine.- Decision Making.- Declarative and Non-Declarative Memory.- Declarative Memory.- Early Ventral Hippocampal Lesion Model.- Eating and Appetite.- Eating Disorder: Anorexia Nervosa.- Eating Disorders: Animal Models.- Eating Disorders: Binge-Eating.- Echolalia.- FAA.- Face Validity.- Facial Dysmorphology.- False Memory.- False Negative.- False Positive.- G protein-Coupled Receptors.- GABA.- GABAA Receptor.- GABAergic Transmission.- Gabapentin.- Galantamine.- Habit Reversal Therapy.- Habit Reversal Training.- Habituation.- Half-Life.- Hallucinations.- Hallucinogen Abuse.- IACUC.- ICD.- Idiopathic.- Imaging Mass Spectrometry.- Imipramine.- Impairment of Functioning; Measurement Scales.- Kappa-Opioid Agonists.- Kappa-Receptor.- Keratotic Lesion.- Ketamine.- Ketamine.- Khat.- L-Alpha-Acetyl-Methadol.- Lamotrigine.- Lanreotide.- Latent Inhibition.- Latin Square Design.- Laxatives.- Magnetic Resonance Imaging.- Major and Minor and Mixed Anxiety-Depressive Disorders.- Major Tranquilizer.- Mania.- MAO-B Inhibitor.- Mass Spectrometry.- N-Acetylcysteine.- Nafion.- Naloxone.- Naltrexone.- N-Arachidonylethanolamine.- Narcolepsy.- ob/ob Mouse.- Obsessions.- Obsessive-Compulsive Anxiety Disorders.- Occasion Setting with Drugs.- Octreotide.- Off-Label Use of Drugs.- P300.- Pain.- Pain and Psychopharmacology.- Pair-Feeding.- Palatability.- Paliperidone.- qEEG.- QT Interval.- Quality of Life.- Quazepam.- Quetiapine.- Radial Arm Maze.- Radionuclide.- Radiopharmaceutical.- Radiotracer.- Randomized Controlled Trials.- Rapamycin.- Saporin.- Satiety.- Saturation Binding Curve.- Scalar Property.- Schedule I.- Schedule II.- Tachykinins.-Tachyphylaxis.- Tandospirone.- Tardive Dyskinesia.- Taste Reactivity Test.- Temazepam.- Ubiquitin-Proteasome System.- Ultrasonic.- Ultrasonic Vocalizations.- Ultrasonic Vocalizations.- Unblocking.- Unconditional Response.- Vaccination.- Vaccines and Drug-Specific Antibodies.- Vagus Nerve Stimulation.- Valproic Acid.- Values-Based Medicine.- Varenicline.- Wakefulness.- Water Maze.- Whole-Cell Recording.- Wisconsin Card Sorting Test.- Wisconsin General Test Apparatus.- Withdrawal Syndromes.- Yale-Brown Obsessive-Compulsive Scale.- Yohimbine.- Zaleplon.- Zero-Order Elimination Kinetics.- Ziprasidone.- Zolpidem.- Zonisamide.- Zopiclone.